{"id":22948,"date":"2026-06-15T14:15:49","date_gmt":"2026-06-15T14:15:49","guid":{"rendered":"https:\/\/www.drfz.de\/?p=22948"},"modified":"2026-06-15T14:17:39","modified_gmt":"2026-06-15T14:17:39","slug":"launch-of-lit-drfz-joint-group-experimental-cell-therapy","status":"publish","type":"post","link":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/","title":{"rendered":"Launch of LIT \/ DRFZ Joint Group \u201cExperimental Cell Therapy\u201d"},"content":{"rendered":"\n

Transferring Research Into Practice For Patients With Rheumatic Diseases<\/strong><\/h2>\n\n\n\n

Common press release (LIT & DRFZ)<\/p>\n\n\n\n

The Leibniz Institute for Immunotherapy (LIT) and the German Rheumatology Research Center, (DRFZ)<\/strong><\/strong>, a Leibniz-Institute are initiating an Independent Joint Experimental Cell Therapy Research Group. This joint venture merges the engineered immune cell therapy expertise of the LIT and the expertise in immune-mediated inflammatory diseases of the DRFZ. The Joint Group \u201cExperimental Cell Therapy\u201d will be headed by Dr. Erica R. Vander Mause, an expert in gene and cellular therapies who has worked extensively with advanced gene editing techniques, primary stem and immune cell culture, and protein engineering.<\/strong><\/p>\n\n\n\n

The aim of this group is to explore and develop the emerging disruptive potential of genetically engineered immune cells, including for example CAR T cells and Treg cells, for the treatment of rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematodes and further inflammatory indications. The group is rolled out for an initial period of 5 years with a potential for prolongation. <\/p>\n\n\n\n

\u201cI am excited to bring my experiences from academic and industry groups to translate the newest clinical insights into more effective therapies for patients,\u201d Erica Vander Mause<\/strong> says.<\/p>\n\n\n\n

\u201cWe are launching an innovative pilot project that will establish a long-term partnership between two complementary Leibniz Institutes and advance the translational value chain,\u201d says Prof. Dr. Philipp Beckhove<\/strong>, Scientific Director of the LIT, outlining the perspectives.<\/p>\n\n\n\n

Being primarily located at the DRFZ in Berlin with additional activities at the LIT, it will be embedded into a highly innovative and supportive scientific and clinical environment at both sites with their expertise in immune tolerance research, genetic engineering and GMP grade cell production (LIT) as well as cutting-edge technologies in molecular and cellular immunology, in vivo disease models and clinical cohorts (DRFZ\/Charit\u00e9).<\/p>\n\n\n\n

\u201cThe LIT\u2013DRFZ joint research group will combine our institutes’ core strengths to advance novel genetically engineered T\u2011cell therapies that are precisely tailored to clinical needs and that improve patients’ quality of life\u201d, states Prof. Dr. Markus Feuerer, Deputy Scientific Director LIT and Head of Research Division \u201cImmunology\u201d, mentoring the group from LIT side.<\/p>\n\n\n\n

\u201cThis joint group creates an important bridge between the cell engineering and immunotherapy expertise of the LIT and the clinical and scientific environment of Charit\u00e9 and DRFZ. Rheumatology is entering a new medical era in which cellular therapies may no longer be limited to cancer, but could fundamentally change how we treat severe immune-mediated diseases. With Erica Vander Mause\u2019s technical expertise in gene editing, immune-cell engineering and translational cell therapy, we are bringing exactly the right capabilities into this rapidly evolving field, with the clear goal of moving innovative science closer to patients\u201d, states Prof. Dr. Eicke Latz<\/strong>, Scientific Director of the DRFZ.<\/p>\n\n\n\n

Both institutions are engaged in a strategic collaboration to improve the quality of life of patients with rheumatic diseases, close gaps in care and open up new avenues in cellular rheumatism therapy \u2013 by transferring research into practice.<\/p>\n\n\n\n

\n
\n
Link to LIT<\/a><\/div>\n<\/div>\n<\/blockquote>\n\n\n\n
\n\n
\n \n \n
\n\n \n
\n \n \n \n <\/div>\n\n <\/div>\n <\/div>\n\n <\/section>\n\n\n\n\n
\n\n
\n

Memorandum of Understanding<\/h2>\n \n \n
\n\n
\n \"Foto <\/div>\n \n
\n \n \n
\n

Prof. Dr. Philipp Beckhove, Scientific Director of LIT, and Prof. Dr. Eicke Latz, Scientific Director at the German Rheumatology Research Center (right) \u00a9 LIT<\/p>\n <\/div>\n \n <\/div>\n\n <\/div>\n <\/div>\n\n <\/section>\n\n","protected":false},"excerpt":{"rendered":"

Transferring Research Into Practice For Patients With Rheumatic Diseases Common press release (LIT & DRFZ) The Leibniz Institute for Immunotherapy (LIT) and the German Rheumatology\u2026<\/p>\n","protected":false},"author":4,"featured_media":22949,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[288,292],"tags":[497],"programme-area-tax":[182],"working-group-tax":[],"class_list":["post-22948","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-for-patients","category-news-en","tag-program-area-4","programme-area-tax-programme-area-4"],"acf":[],"yoast_head":"\nLaunch of LIT \/ DRFZ Joint Group \u201cExperimental Cell Therapy\u201d - DRFZ<\/title>\n<meta name=\"description\" content=\"Dr. Erica R. Vander Mause will lead the joint \u201cExperimental Cell Therapy\u201d group at the Leibniz-Institutes DRFZ and LIT.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Launch of LIT \/ DRFZ Joint Group \u201cExperimental Cell Therapy\u201d - DRFZ\" \/>\n<meta property=\"og:description\" content=\"Dr. Erica R. Vander Mause will lead the joint \u201cExperimental Cell Therapy\u201d group at the Leibniz-Institutes DRFZ and LIT.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"DRFZ\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/drfz.de\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T14:15:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T14:17:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.drfz.de\/wp-content\/uploads\/2026\/06\/26_06_01_Erica-Vander-Mause_Beitrag-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ute Hoffmann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DRFZ_Berlin\" \/>\n<meta name=\"twitter:site\" content=\"@DRFZ_Berlin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ute Hoffmann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\\\/\"},\"author\":{\"name\":\"Ute Hoffmann\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#\\\/schema\\\/person\\\/a86dc60d63c6fa52cb3ee62f12c72737\"},\"headline\":\"Launch of LIT \\\/ DRFZ Joint Group \u201cExperimental Cell Therapy\u201d\",\"datePublished\":\"2026-06-15T14:15:49+00:00\",\"dateModified\":\"2026-06-15T14:17:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\\\/\"},\"wordCount\":502,\"publisher\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/26_06_01_Erica-Vander-Mause_Beitrag-1.jpg\",\"keywords\":[\"Program area 4\"],\"articleSection\":[\"For patients\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\\\/\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\\\/\",\"name\":\"Launch of LIT \\\/ DRFZ Joint Group \u201cExperimental Cell Therapy\u201d - DRFZ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/26_06_01_Erica-Vander-Mause_Beitrag-1.jpg\",\"datePublished\":\"2026-06-15T14:15:49+00:00\",\"dateModified\":\"2026-06-15T14:17:39+00:00\",\"description\":\"Dr. Erica R. Vander Mause will lead the joint \u201cExperimental Cell Therapy\u201d group at the Leibniz-Institutes DRFZ and LIT.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/26_06_01_Erica-Vander-Mause_Beitrag-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/26_06_01_Erica-Vander-Mause_Beitrag-1.jpg\",\"width\":1280,\"height\":720,\"caption\":\"Portrait photo of Erica Vander Mause\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Launch of LIT \\\/ DRFZ Joint Group \u201cExperimental Cell Therapy\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/\",\"name\":\"DRFZ\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#organization\",\"name\":\"Deutsches Rheuma-Forschungszentrum\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/drfz-footer-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/drfz-footer-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Deutsches Rheuma-Forschungszentrum\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/drfz.de\\\/\",\"https:\\\/\\\/x.com\\\/DRFZ_Berlin\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/deutsches-rheuma-forschungszentrum-berlin\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCf8nDuqpkWwcmCWmfSTkE3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#\\\/schema\\\/person\\\/a86dc60d63c6fa52cb3ee62f12c72737\",\"name\":\"Ute Hoffmann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/08c654ead40d6cafc50e4ed4fbf2fe4a8a979f96141a813138eec621e1d2879f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/08c654ead40d6cafc50e4ed4fbf2fe4a8a979f96141a813138eec621e1d2879f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/08c654ead40d6cafc50e4ed4fbf2fe4a8a979f96141a813138eec621e1d2879f?s=96&d=mm&r=g\",\"caption\":\"Ute Hoffmann\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Launch of LIT \/ DRFZ Joint Group \u201cExperimental Cell Therapy\u201d - DRFZ","description":"Dr. Erica R. Vander Mause will lead the joint \u201cExperimental Cell Therapy\u201d group at the Leibniz-Institutes DRFZ and LIT.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Launch of LIT \/ DRFZ Joint Group \u201cExperimental Cell Therapy\u201d - DRFZ","og_description":"Dr. Erica R. Vander Mause will lead the joint \u201cExperimental Cell Therapy\u201d group at the Leibniz-Institutes DRFZ and LIT.","og_url":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/","og_site_name":"DRFZ","article_publisher":"https:\/\/www.facebook.com\/drfz.de\/","article_published_time":"2026-06-15T14:15:49+00:00","article_modified_time":"2026-06-15T14:17:39+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/www.drfz.de\/wp-content\/uploads\/2026\/06\/26_06_01_Erica-Vander-Mause_Beitrag-1.jpg","type":"image\/jpeg"}],"author":"Ute Hoffmann","twitter_card":"summary_large_image","twitter_creator":"@DRFZ_Berlin","twitter_site":"@DRFZ_Berlin","twitter_misc":{"Written by":"Ute Hoffmann","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/#article","isPartOf":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/"},"author":{"name":"Ute Hoffmann","@id":"https:\/\/www.drfz.de\/en\/#\/schema\/person\/a86dc60d63c6fa52cb3ee62f12c72737"},"headline":"Launch of LIT \/ DRFZ Joint Group \u201cExperimental Cell Therapy\u201d","datePublished":"2026-06-15T14:15:49+00:00","dateModified":"2026-06-15T14:17:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/"},"wordCount":502,"publisher":{"@id":"https:\/\/www.drfz.de\/en\/#organization"},"image":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.drfz.de\/wp-content\/uploads\/2026\/06\/26_06_01_Erica-Vander-Mause_Beitrag-1.jpg","keywords":["Program area 4"],"articleSection":["For patients","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/","url":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/","name":"Launch of LIT \/ DRFZ Joint Group \u201cExperimental Cell Therapy\u201d - DRFZ","isPartOf":{"@id":"https:\/\/www.drfz.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.drfz.de\/wp-content\/uploads\/2026\/06\/26_06_01_Erica-Vander-Mause_Beitrag-1.jpg","datePublished":"2026-06-15T14:15:49+00:00","dateModified":"2026-06-15T14:17:39+00:00","description":"Dr. Erica R. Vander Mause will lead the joint \u201cExperimental Cell Therapy\u201d group at the Leibniz-Institutes DRFZ and LIT.","breadcrumb":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/#primaryimage","url":"https:\/\/www.drfz.de\/wp-content\/uploads\/2026\/06\/26_06_01_Erica-Vander-Mause_Beitrag-1.jpg","contentUrl":"https:\/\/www.drfz.de\/wp-content\/uploads\/2026\/06\/26_06_01_Erica-Vander-Mause_Beitrag-1.jpg","width":1280,"height":720,"caption":"Portrait photo of Erica Vander Mause"},{"@type":"BreadcrumbList","@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/launch-of-lit-drfz-joint-group-experimental-cell-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.drfz.de\/en\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.drfz.de\/en\/news\/"},{"@type":"ListItem","position":3,"name":"Launch of LIT \/ DRFZ Joint Group \u201cExperimental Cell Therapy\u201d"}]},{"@type":"WebSite","@id":"https:\/\/www.drfz.de\/en\/#website","url":"https:\/\/www.drfz.de\/en\/","name":"DRFZ","description":"","publisher":{"@id":"https:\/\/www.drfz.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.drfz.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.drfz.de\/en\/#organization","name":"Deutsches Rheuma-Forschungszentrum","url":"https:\/\/www.drfz.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.drfz.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/10\/drfz-footer-logo.svg","contentUrl":"https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/10\/drfz-footer-logo.svg","width":1,"height":1,"caption":"Deutsches Rheuma-Forschungszentrum"},"image":{"@id":"https:\/\/www.drfz.de\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/drfz.de\/","https:\/\/x.com\/DRFZ_Berlin","https:\/\/www.linkedin.com\/company\/deutsches-rheuma-forschungszentrum-berlin","https:\/\/www.youtube.com\/channel\/UCf8nDuqpkWwcmCWmfSTkE3w"]},{"@type":"Person","@id":"https:\/\/www.drfz.de\/en\/#\/schema\/person\/a86dc60d63c6fa52cb3ee62f12c72737","name":"Ute Hoffmann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/08c654ead40d6cafc50e4ed4fbf2fe4a8a979f96141a813138eec621e1d2879f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/08c654ead40d6cafc50e4ed4fbf2fe4a8a979f96141a813138eec621e1d2879f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/08c654ead40d6cafc50e4ed4fbf2fe4a8a979f96141a813138eec621e1d2879f?s=96&d=mm&r=g","caption":"Ute Hoffmann"}}]}},"_links":{"self":[{"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/posts\/22948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/comments?post=22948"}],"version-history":[{"count":7,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/posts\/22948\/revisions"}],"predecessor-version":[{"id":23164,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/posts\/22948\/revisions\/23164"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/media\/22949"}],"wp:attachment":[{"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/media?parent=22948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/categories?post=22948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/tags?post=22948"},{"taxonomy":"programme-area-tax","embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/programme-area-tax?post=22948"},{"taxonomy":"working-group-tax","embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/working-group-tax?post=22948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}